Wells Fargo initiated coverage on Septerna with a new price target
$SEPN
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Septerna with a rating of Overweight and set a new price target of $43.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
10-Q - Septerna, Inc. (0001984086) (Filer)
Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
TD Cowen initiated coverage of Septerna with a rating of Buy
Wells Fargo initiated coverage of Septerna with a rating of Overweight and set a new price target of $43.00
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of the company's website at www.septerna.com and will be archived for 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by i
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today reported financial results for the third quarter ended September 30, 2024 and provided a portfolio overview and busines
3 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
SC 13D - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)